Bluebird bio Total Current Liabilities

Bluebird bio (BLUE) currently reports a total current liabilities of $320M as of March 2025. That compares with $290M in the prior-year period — up 7.3% year over year. Use the charts on this page to explore Bluebird bio's total current liabilities history and peer comparisons.

Bluebird bio's total current liabilities increased from $290M to $320M — a 7.3% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bluebird bio reported $320M in total current liabilities as of March 2025. That compares with $290M in the prior-year period — up 7.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $320M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.

Bluebird bio is classified in the Healthcare sector. On total current liabilities, it currently shows $320M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLUE with unrelated industries.